2026-01-08 東京大学
DLco による CTEPH 患者の臨床イベント
<関連情報>
- https://www.h.u-tokyo.ac.jp/press/20260108.html
- https://www.h.u-tokyo.ac.jp/press/__icsFiles/afieldfile/2026/01/08/release_20260108.pdf
- https://thorax.bmj.com/content/early/2026/01/02/thorax-2025-223670
慢性血栓塞栓性肺高血圧症における一酸化炭素肺拡散能の重要性 Significance of diffusing capacity of the lungs for carbon monoxide on chronic thromboembolic pulmonary hypertension
Shun Minatsuki,Masaru Hatano,Kouta Funakoshi,Yu Taniguchi,Shiro Adachi,Takumi Inami,Kazuya Hosokawa,Jun Yamashita,Hitoshi Ogino,Ichizo Tsujino,Nobuhiro Yaoita,Nobutaka Ikeda,Nobuhiro Tanabe,Hiroto Shimokawahara,Kayoko Kubota,Ayako Shigeta,Koichiro Tatsumi,Koshin Horimoto,Yoshito Ogihara,Yoshihiro Dohi,Takahiro Hiraide,Takashi Kawakami,Hidekazu Ikemiyagi,Yuichi Tamura,Yoshihiro Fukumoto,Kohtaro Abeon behalf of CTEPH AC Registry Study Group
Thorax Publisjed:January 7, 2026
DOI:https://doi.org/10.1136/thorax-2025-223670
Abstract
Reduced diffusing capacity of the lungs for carbon monoxide (DLco) reflects microvasculopathy in chronic thromboembolic pulmonary hypertension, yet its clinical value is uncertain. In a Japanese nationwide registry (2018–2023) we studied 1270 patients: 486 formed an event cohort and 299 a treatment cohort who underwent pulmonary endarterectomy or balloon pulmonary angioplasty. Lower baseline DLco was indicative of smaller postprocedural improvements in mean pulmonary artery pressure, pulmonary vascular resistance and cardiac index (all p≤0.023) and a higher risk of clinical events (HR 0.971, p=0.005). Outcomes deteriorated below 59.6%, indicating DLco may help stratify prognosis and treatment benefit.
